Glaucoma
Conditions
Interventions
Study Group:The patient undergoes cataract surgery and implantation of an intraocular lens (astigmatism or non-astigmatism) followed by implantation of the iStent inject W device.
Sponsors
The Second Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=40 years, gender is not limited. 2. Clinically confirmed diagnosis of mild to moderate primary open-angle glaucoma (visual field MD dB <= -12) who is receiving topical intraocular hypotensive medication. 3. Good eye health, no other lesions affecting vision (except for residual refractive error, cataract and glaucoma), and both eyes must meet the ocular standards. 4. Planned to undergo routine cataract surgery. 5. Able to understand and willing to sign an informed consent document, willing and able to participate in standard preoperative and postoperative study visits.
Exclusion criteria
Exclusion criteria: 1. Primary angle-closure glaucoma, secondary angle-closure glaucoma (including neovascular glaucoma). 2. Have retrobulbar tumors, thyroid eye disease, Sturge - Weber syndrome, or other conditions that may cause elevated extrascleral venous pressure. 3. Amblyopia. 4. Previous anterior or posterior chamber surgery (such as vitrectomy, laser iridotomy, glaucoma filtration surgery and elective laser trabeculoplasty within 90 days prior to screening, etc.). 5. History of diabetic retinopathy, macular degeneration, retinal detachment. 6. Acute or chronic diseases known to affect postoperative vision (such as immunocompromise, connective tissue diseases, clinically evident atopic diseases, diabetes mellitus and any other such diseases). 7. Pregnant or lactating women (pregnancy and lactation may affect the results of the study, and there is a lack of adequate studies of pregnant women, and they are not included unless the potential benefits outweigh the risks to the fetus).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post operation IOP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Field;Numbers of antiglaucoma eye drops;Surgical complications; | — |
Countries
China
Contacts
Public ContactPeng Lu
The Second Hospital of Lanzhou University
Outcome results
None listed